ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
High-acceleration pancreatobiliary MRI with deep learning-based super-resolution reconstruction for evaluating presumed pancreatic intraductal papillary mucinous neoplasm.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo evaluate the feasibility and diagnostic utility of a deep learning (DL)-based super-resolution (SR) reconstruction algorithm applied to pancreatobiliary MRI for assessing pancreatic intraductal papillary mucinous neoplasms (IPMNs).
methodsThis retrospective study included 162 patients with presumed pancreatic IPMN (≥ 1 cm) who underwent pancreatobiliary MRI between May 2019 and May 2022. Two portal venous phase (PVP) images of dynamic T1-wegithed imaging were sequentially acquired: early PVP image obtained using standard compressed sensing (CS)-volumetric interpolated breath-hold examination (VIBE) (standard CS-VIBE) and late PVP image obtained using CS-VIBE with DL-based SR reconstruction algorithm to generate 1 mm-thickness images (DL-SR CS-VIBE). Arterial phase and 3-min delayed phase were also acquired using DL-SR CS-VIBE. The image quality of standard and DL-SR CS-VIBE PVP sequences was compared using Wilcoxon signed-rank test. The diagnostic performance of full-sequence pancreatobiliaryMRI including DL-SR CS-VIBE for predicting malignant IPMN was assessed using multi-reader multi-case analysis. Diagnostic accuracy was assessed using receiver operating characteristic analysis, while sensitivity and specificity were estimated with corresponding 95% confidence intervals.
resultsAmong 162 patients, 15 had malignant IPMN, while 147 had benign IPMN. DL-SR CS-VIBE demonstrated significantly better overall image quality (3.73 ± 0.33 vs. 3.22 ± 0.43) and cystic lesion conspicuity (3.37 ± 0.50 vs. 2.71 ± 0.52) than standard CS-VIBE (all Ps < 0.001). The area under the ROC curve (AUC) for predicting malignant IPMN was 0.858 (95% CI: 0.807, 0.909). Using the presence of high-risk stigmata as an indicator of test-positive, pooled sensitivity and pooled specificity of pancreatobiliary MRI including DL-SR CS-VIBE for malignant IPMN were 71.1% (95% confidence interval [CI]: 55.7, 83.6) and 82.8% (95% CI: 78.9, 86.2), respectively. Among MRI features, diagnostic accuracy was highest for mural nodules ≥ 5 mm (AUC, 0.736) and main pancreatic duct size ≥ 10 mm (AUC, 0.720).
conclusionPancreatobiliary MRI with DL-SR CS-VIBE enhances image quality and lesion conspicuity, offering promising diagnostic accuracy for malignant IPMN, though further studies with larger cohorts are needed to refine these findings and evaluate clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.